NCT02340988 - Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Healthy

Interventions

DRUG

Single-Dose IV Oritavancin Diphosphate and Warfarin

Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.

DRUG

Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose

Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.

Trial Locations (1)

53095

Spaulding Clinical, West Bend